Adoptive immunotherapy, wherein tumor-specific CTLs are activated and expanded in vitro with bryostatin and ionomycin, that were infused back into the body of the animals, has greater regression of established melanoma and 4T1 mammary carcinomas in vivo if the cells were cultured in IL-7 and IL-15 compared with IL-2 alone [46,47]. The gene discussed is IL7; the disease is neoplasm.